ManaFlexx 2 (model: MF002-RX, MF002-OTC)

K231569 · Manamed, Inc. · NUH · Nov 3, 2023 · Neurology

Device Facts

• Record ID: K231569
• Device Name: ManaFlexx 2 (model: MF002-RX, MF002-OTC)
• Applicant: Manamed, Inc.
• Product Code: NUH · Neurology
• Decision Date: Nov 3, 2023
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 882.5890
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

For Over-The-Counter Use: TENS: ManaFlexx 2 (MF002-OTC) is used for temporary relief of pain associated with sore and aching muscles in the shoulder, waist, back, arm, and leg, due to strain from exercise or normal household and work activities. ManaFlexx 2 (MF002-OTC) is also intended for symptomatic relief and management of chronic, intractable pain and relief of pain associated with arthritis. PMS/NMES: ManaFlexx 2 (MF002-OTC) is used to stimulate healthy muscles in order to improve and facilitate muscle performance. To be used for the improvement of muscle tone and firmness, and for strengthening muscles in the arms, abdomen, legs, and buttocks. Not intended for use in any therapy or for the treatment of any medical conditions or diseases. ManaFlexx 2 (MF002-OTC)is also intended to temporarily increase local blood circulation in the healthy muscles of lower extremities. For Prescription Use: TENS: ManaFlexx 2 (MF002-RX) is intended for the following use: - Symptomatic relief and management of chronic, intractable pain - Adjunctive treatment for post-surgical and post-trauma acute pain - Relief of pain associated with arthritis PMS/NMES: ManaFlexx 2 (MF002-RX) is intended for the following use: - Temporary relaxation of muscle spasm - Prevention or retardation of disuse atrophy - Muscle re-education - Maintaining or increasing range of motion - Increase of local blood flow in the treatment area - Prevention of post-surgical venous thrombosis through immediate stimulation of calf muscles

Device Story

ManaFlexx 2 is a TENS and PMS/NMES device delivering electric pulses to body areas via conductive hydrogel electrodes. The egg-shaped main unit features an LED display, ON/OFF button, and intensity controls. It operates via two program modes with varying pulse frequencies. The device is used in home or clinical settings by patients (OTC) or healthcare providers (RX) to manage pain, improve muscle performance, or facilitate muscle rehabilitation. Users apply the strip-shaped electrode to the target area and adjust intensity levels. The device output affects nerve/muscle stimulation, providing symptomatic pain relief, muscle strengthening, or increased blood flow. It is powered by a rechargeable battery.

Clinical Evidence

No clinical data. Bench testing only, including electrical safety (ANSI AAMI ES60601-1), electromagnetic compatibility (IEC 60601-1-2), and performance testing for nerve/muscle stimulators (IEC 60601-2-10).

Technological Characteristics

ABS plastic housing; rechargeable battery power; biphasic waveform; regulated voltage control; two snap-connector electrode interface; conductive hydrogel electrodes. Complies with IEC 60601-1, IEC 60601-1-2, IEC 60601-1-11, and IEC 60601-2-10. Software is microprocessor-controlled.

Indications for Use

Indicated for OTC use for temporary relief of pain in shoulder, waist, back, arm, leg due to strain; symptomatic relief of chronic, intractable pain; relief of arthritis pain; improvement of muscle tone/firmness/strength in arms, abdomen, legs, buttocks; and temporary increase of local blood circulation in lower extremities. Indicated for prescription use for chronic, intractable pain; post-surgical/post-trauma acute pain; arthritis pain; muscle spasm relaxation; prevention/retardation of disuse atrophy; muscle re-education; maintenance/increase of range of motion; increase of local blood flow; and prevention of post-surgical venous thrombosis.

Regulatory Classification

Identification

A transcutaneous electrical nerve stimulator for pain relief is a device used to apply an electrical current to electrodes on a patient's skin to treat pain.

Predicate Devices

• JKH Stimulator Plus (K191151)

Reference Devices

• Transcutaneous Electronic Nerve Stimulator (K200237)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the seal of the Department of Health and Human Services. To the right of that is the FDA logo, which consists of a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG" in blue, and the word "ADMINISTRATION" in a smaller font size below that.

November 3, 2023

ManaMed, Inc % Cassie Lee Manager Guangzhou GLOMED Biological Technology Co., Ltd. 2231, Building 1, Rui Feng Center, Kaichuang Road Huangpu District Guangzhou, Guangdong 510000 China

Re: K231569

Trade/Device Name: ManaFlexx 2 (model: MF002-RX. MF002-OTC) Regulation Number: 21 CFR 882.5890 Regulation Name: Transcutaneous electrical nerve stimulator for pain relief Regulatory Class: Class II Product Code: NUH, NGX, NYN, GZJ, IPF Dated: May 25, 2023 Received: May 31, 2023

Dear Cassie Lee:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (OS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

{2}------------------------------------------------

Sincerely,

# Robert Kang -S

for Pamela Scott, MS Assistant Director DHT5B: Division of Neuromodulation and Rehabilitation Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

# Indications for Use

510(k) Number (if known) K231569

Device Name ManaFlexx 2(Model: MF002-RX, MF002-OTC)

Indications for Use (Describe) For Over-The-Counter Use:

TENS:

ManaFlexx 2 (MF002-OTC) is used for temporary relief of pain associated with sore and aching muscles in the shoulder, waist, back, arm, and leg, due to strain from exercise or normal household and work activities. ManaFlexx 2 (MF002-OTC) is also intended for symptomatic relief and management of chronic, intractable pain and relief of pain associated with arthritis.

#### PMS/NMES:

ManaFlexx2 (MF002-OTC) is used to stimulate healthy muscles in order to improve and facilitate muscle performance. To be used for the improvement of muscle tone and firmness, and for strengthening muscles in the arms, abdomen, legs, and buttocks. Not intended for use in any therapy or for the treatment of any medical conditions or diseases. ManaFlexx2 (MF002-OTC) is also intended to temporarily increase local blood circulation in the healthy muscles of lower extremities.

For Prescription Use:

TENS:

ManaFlexx2 (MF002-RX) is intended for the following use:

- Symptomatic relief and management of chronic, intractable pain
- Adjunctive treatment for post-surgical and post-trauma acute pain
- Relief of pain associated with arthritis

#### PMS/NMES:

ManaFlexx2 (MF002-RX) is intended for the following use:

- Temporary relaxation of muscle spasm
- Prevention or retardation of disuse atrophy
- Muscle re-education
- Maintaining or increasing range of motion
- Increase of local blood flow in the treatment area
- Prevention of post-surgical venous thrombosis through immediate stimulation of calf muscles

Type of Use (Select one or both, as applicable)

> Prescription Use (Part 21 CFR 801 Subpart D)

|X Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

{4}------------------------------------------------

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{5}------------------------------------------------

# 510(k) Summary

This summary of 510(K) safety and effectiveness information is being submitted in accordance with the requirement of 21 CFR 801.92.

# 1. Submitter's Information

Name: ManaMed Inc Address: 5240 W. Charleston Blvd. Suite 150.Las Vegas, NV 89146.USA Postal code: 89146 Contact name: Trevor Theriot Title: President Tel: [phone] Fax: [phone] E-mail: [e-mail]

# Application Correspondent:

Contact Person: Ms. Cassie Lee Guangzhou GLOMED Biological Technology Co., Ltd. Address: 2231, Building 1, Rui Feng Center, Kaichuang Road, Huangpu District, Guangzhou, Guangdong, China Tel: [phone] Email: [e-mail]

# 2. Date of the summary prepared: November 1, 2023

# 3. Subject Device Information

Common Name: Transcutaneous Electrical Nerve Stimulation (TENS) unit, Powered Muscle Stimulation (PMS) unit, blood circulation, and muscle performance Trade Name: ManaFlexx 2 Classification Name: Stimulator, Nerve, Transcutaneous, Over-the-Counter Model: MF002-RX, MF002-OTC Regulatory Class: II Product Code: NUH, NGX, NYN, GZJ, IPF Regulation Number: 21 CFR 882.5890

4. Predicate Device Information Predicate Device1 (Primary):

{6}------------------------------------------------

510(K) Number: K191151 Company Name: JKH USA, LLC Address: 1142 S. Diamond Bar Blvd, #861, Diamond Bar, CA 91765 Trade Name: JKH Stimulator Plus Model: PL-029K5BL, PL-029K15, PL-029T Regulation Number: 21 CFR 882.5890\ Regulatory Class: II Product Code: NUH, NGX, NYN, GZJ, IPF, IRT

## Reference Device:

510(K) Number: K200237 Company Name: Shenzhen Kentro Medical Electronics Co., Ltd Address: No.3, Xihu industry zone, Xikeng Village, Henggang Town, Longgang District, Shenzhen, Guangdong, China Trade Name: Transcutaneous Electronic Nerve Stimulator Model: KTR-2401, KTR-2402, KTR-2411, KTR-2412, KTR-2302, KTR-2302, KTR-2341, KTR-2342, KTR-2491, KTR-2492, KTR-2493, KTR-2494. Regulation Number: 21 CFR 890.5850 Regulatory Class: II Product Code: NUH

# 5. Device Description

The ManaFlexx 2 delivers electric pulse generated to the user's body areas through the electrodes. The device has two program modes of different pulse frequencies, covering TENS and PMS/NMES. The main unit is egg shape, includes operating elements, such as the ON/OFF button, intensity increase button and intensity decrease button, and there are two snap connectors on the rear of the device which are for connecting with electrode. The device could be easily operated through its buttons to manually realize its functions, such as turning on/off and increasing/decreasing intensity, and there is a LED screen to display the selected mode, intensity level and charging status.

The electrode is a long strip shape with a size of 21cm x 5.3cm, its conductive part is black color, and there is white non-conductive area with a width of 1 cm in the middle, which divides the electrode into two parts: positive and negative. There are 2 snap connectors on the electrode used for connection with main unit.

The device has two models have the same appearance, the identical hardware and software, only the model names are different and model MF002-Rx is for prescription use and MF002-OTC is for OTC use.

{7}------------------------------------------------

# 6. Intended Use / Indications for Use

For Over-The-Counter Use: TENS:

ManaFlexx 2 (MF002-OTC) is used for temporary relief of pain associated with sore and aching muscles in the shoulder, waist, back, arm, and leg, due to strain from exercise or normal household and work activities.

ManaFlexx 2 (MF002-OTC) is also intended for symptomatic relief and management of chronic, intractable pain and relief of pain associated with arthritis.

# PMS/NMES:

ManaFlexx 2 (MF002-OTC) is used to stimulate healthy muscles in order to improve and facilitate muscle performance. To be used for the improvement of muscle tone and firmness, and for strengthening muscles in the arms, abdomen, legs, and buttocks. Not intended for use in any therapy or for the treatment of any medical conditions or diseases.

ManaFlexx 2 (MF002-OTC)is also intended to temporarily increase local blood circulation in the healthy muscles of lower extremities.

# For Prescription Use:

# TENS:

ManaFlexx 2 (MF002-RX) is intended for the following use:

- Symptomatic relief and management of chronic, intractable pain
- Adjunctive treatment for post-surgical and post-trauma acute pain
- Relief of pain associated with arthritis

# PMS/NMES:

ManaFlexx 2 (MF002-RX) is intended for the following use:

- Temporary relaxation of muscle spasm
- Prevention or retardation of disuse atrophy
- Muscle re-education
- Maintaining or increasing range of motion
- Increase of local blood flow in the treatment area
- Prevention of post-surgical venous thrombosis through immediate stimulation of calf muscles

# 7. Comparison to predicate device and conclusion

Compare with predicate device, the subject device is very similar in design principle, intended use, indications for use, functions, material and the applicable standards. The differences between subject device and predicate device do not raise and new questions of safety or effectiveness.

{8}------------------------------------------------

| Elements of Comparison | Subject Device | Primary Predicate Device | Reference Device | Remark | |
|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|---------------------|
| Device Name and Model | ManaFlexx 2 (MF002-RX, MF002-OTC) | JKH Stimulator Plus (PL-029K5BL, PL-029K15, PL-029T) | Transcutaneous<br>Electronic Nerve<br>Stimulator (Model:<br>KTR-2401, KTR-2402,<br>KTR-2411, KTR-2412,<br>KTR-2301, KTR-2302,<br>KTR-2341, KTR-2342,<br>KTR-2491, KTR-2492,<br>KTR-2493, KTR-2494) | -- | |
| 510(k) Number | K231569 | K191151 | K200237 | -- | |
| Product Code | NUH, NGX, NYN, GZJ, IPF | NUH, NGX, NYN, GZJ, IPF, IRT | NUH | Similar<br>Note 1 | |
| Intended Use | For Over-The-Counter Use:<br>TENS:<br>ManaFlexx 2 (MF002-OTC) is used for temporary relief of pain associated with sore and aching muscles in the shoulder, waist, back, arm, and leg, due to strain from exercise or normal household and work activities.<br>ManaFlexx 2 (MF002-OTC) is also intended for symptomatic relief and management of chronic, intractable pain and relief of pain associated with arthritis.<br><br>PMS/NMES:<br>ManaFlexx 2 (MF002-OTC) is used to stimulate healthy muscles in order to improve and facilitate muscle performance. To be used for the improvement of muscle tone and firmness, and for strengthening muscles in the arms, abdomen, legs, and buttocks. Not intended for use in any therapy or for the treatment of any medical conditions or diseases.<br>ManaFlexx 2 (MF002-OTC)is also intended to temporarily increase local blood circulation in the healthy muscles of lower extremities. | Over-The-Counter Use:<br>TENS:<br>PL-029K5BL, PL-029K15, and PL-029T are used for temporary relief of pain associated with sore and aching muscles in the shoulder, waist, back, arm, and leg, due to strain from exercise or normal household and work activities.<br>PL-029K5BL, PL-029K15, and PL-029T are also intended for symptomatic relief and management of chronic, intractable pain and relief of pain associated with arthritis.<br>The device of PL-029K5BL and PL-029K15 may be used during sleep.<br>The device of PL-029K5BL and PL-029K15 is labeled for use only with its own compatible electrodes.<br><br>PMS:<br>PL-029K5BL, PL-029K15, and PL-029T are used to stimulate healthy muscles in order to improve and facilitate muscle performance. To be used for the improvement of muscle tone and firmness, and for strengthening muscles in the arms, abdomen, legs, and buttocks. Not intended for | Transcutaneous<br>Electronic Nerve<br>Stimulator is indicated for temporary relief of pain associated with sore and aching muscles in the shoulder, waist, back, neck, upper extremities (arm) and lower extremities (leg) due to strain from exercise or normal household work activities. | Similar<br>Note 1 | |
| | | | | | |
| | For Prescription Use:<br>TENS:<br>ManaFlexx 2 (MF002-RX) is<br>intended for the following<br>use:<br>- Symptomatic relief and<br>management of chronic,<br>intractable pain<br>- Adjunctive treatment for<br>post-surgical and post-<br>trauma acute pain<br>- Relief of pain associated<br>with arthritis<br>PMS/NMES:<br>ManaFlexx 2 (MF002-RX) is<br>intended for the following<br>use:<br>- Temporary relaxation of<br>muscle spasm<br>- Prevention or retardation<br>of disuse atrophy<br>- Muscle re-education<br>- Maintaining or increasing<br>range of motion<br>- Increase of local blood flow<br>in the treatment area<br>- Prevention of post-surgical<br>venous thrombosis through<br>immediate stimulation of calf<br>muscles | use in any therapy or for the<br>treatment of any medical<br>conditions or diseases.<br>PL-029K5BL, PL-029K15,<br>and PL-029T are also<br>intended to temporarily<br>increase local blood<br>circulation in the healthy<br>muscles of lower<br>extremities.<br>Heating: The device of PL-<br>029T is intended for<br>temporary relief of minor<br>aches and pains.<br>Prescription Use:<br>TENS: PL-029K5BL, PL-<br>029K15, and PL-029T are<br>intended for the following<br>use: - Symptomatic relief<br>and management of<br>chronic, intractable pain -<br>Adjunctive treatment for<br>post-surgical and post-<br>trauma acute pain - Relief<br>of pain associated with<br>arthritis<br>PMS: PL-029K5BL, PL-<br>029K15, and PL-029T are<br>intended for the following<br>use: - Temporary relaxation<br>of muscle spasm -<br>Prevention or retardation of<br>disuse atrophy<br>- Muscle re-education<br>- Maintaining or increasing<br>range of motion<br>- Increase of local blood<br>flow in the treatment area<br>- Prevention of post-surgical<br>venous thrombosis through<br>immediate stimulation of<br>calf muscles | | | |
| Prescription or OTC | OTC and Prescription | OTC and Prescription | OTC | Same | |
| Power Source(s) | Rechargeable battery | Rechargeable or non-<br>rechargeable battery | For KTR-23XX<br>series: CR2032;<br>3Vdc; 240mAh<br><br>For KTR-24XX<br>series: PL301526;<br>3.7Vdc, 250mAh | Same | |
| Method of line current<br>isolation | Battery supply | Battery supply | Not public available | Same | |
| Patient leakage current: | <10 µA | N/A | NC: DC: 0.5µA | Different | |
| Normal condition (μΑ) | | | | SFC: DC: 0.6μΑ | Note 2 |
| Patient leakage current: Single Fault condition (μΑ) | | <50 μΑ | N/A | Not public available | Different<br>Note 2 |
| Average DC current through electrodes when device is on but no pulses are being applied (mA) | | 0 | 0 | < 0.01μΑ | Same |
| Number of Output Modes | | 2 | PL-029K5BL: 6-8<br>PL-029K15: 1-4<br>PL-029T: 8 | For KTR-23XX<br>series: 3 modes<br>For KTR-240X series<br>& KTR-241X series: 3<br>modes<br>For KTR 249X series:<br>15 modes | Different<br>Note 3 |
| Number of Output | | 1 | 1-2 | 1 | Same |
| Synchronous/Alternating? | | N/A | N/A | Synchronous | Same |
| Method of Channel Isolation | | N/A | N/A | Not public available | Same |
| Regulated Current or Regulated Voltage? | | Voltage | Voltage | Voltage Control | Same |
| Software/Firmware/<br>Microprocessor Control? | | Yes | Yes | Yes | Same |
| Automatic Overload Trip? | | No | No | No | Same |
| Automatic No-Load Trip? | | Yes | Yes | No | Same |
| Automatic Shut Off? | | Yes | Yes | Yes | Same |
| User Override Control? |…